A brief instrument to assess treatment response in the patient with advanced alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 23, Issue 4, 2009, Pages 377-383

  Schmitt, Frederick A ^a   Saxton, Judith A ^b   Xu, Yikang ^c   McRae, Thomas ^c   Sun, Yijun ^d   Richardson, Sharon ^d   Li, Honglan ^d  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c PFIZER INC   (United States)

^d EISAI INC   (United States)

Author keywords

Alzheimer disease; Assessment; Severe

Indexed keywords

DONEPEZIL; PLACEBO;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; EFFECT SIZE; FEMALE; HUMAN; LANGUAGE ABILITY; MAJOR CLINICAL STUDY; MALE; MEMORY; MINI MENTAL STATE EXAMINATION; ORIENTATION; PRIORITY JOURNAL; RATING SCALE; READING; SCORING SYSTEM; SEVERE IMPAIRMENT BATTERY; SOCIAL INTERACTION; TREATMENT RESPONSE; VALIDATION STUDY; VERBAL COMMUNICATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MALE; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 75949130369     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e3181ac9cc1     Document Type: Article

References (18)

1. Schmitt FA, Wichems CH. A systematic review of assessment and treatment of moderate to severe Alzheimer's disease. Prim Care Companion J Clin Psychiatry. 2006;8:158-159.
2. Saxton J, Swihart AA. Neuropsychological assessment of the severely impaired elderly patient. Clin Geriatr Med. 1989;5: 531-543.
3. Saxton J, McGonigle-Gibson KL, Swihart AA, et al. Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery. Psychol Assess. 1990;2:298-303.
4. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007;69:459-469.
5. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease [published erratum appears in Neurology. 2001;57:2153]. Neurology. 2001;57:613-620.
6. Homma A, Arimoto I, Daidoji MS, et al. Treatment of severe Alzheimer's disease with donepezil: results from a 24-week, parallel, placebo controlled study in Japan. Presented at: 10th International Conference on Alzheimer's Disease and Related Disorders; July 15-20, 2006; Madrid, Spain.
7. Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006;367:1057-1065.
8. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003; 348:1333-1341.
9. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317-324.
10. Qazi A, Richardson B, Simmons P, et al. The Mini-SIB: a short scale for measuring cognitive function in severe dementia. Int J Geriatr Psychiatry. 2005;20:1001-1002.
11. Saxton J, Kastango KB, Hugonot-Diener L, et al. Development of a short form of the Severe Impairment Battery. Am J Geriatr Psychiatry. 2005;13:999-1005.
12. Feldman H, Gauthier S, Hecker J, et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry. 2005;20:559-569.
13. Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
14. Mattis S. Dementia Rating Scale: Professional Manual. Odessa, FL: Psychological Assessment Resources Inc; 1988.
15. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
16. Schmitt FA, Cragar D, Ashford JW, et al. Measuring cognition in advanced Alzheimer's disease for clinical trials. J Neural Transm Suppl. 2002;62:135-148.
17. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging. 2006;10:417-429.
18. Winblad B, Brodaty H, Gauthier S, et al. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry. 2001;16:653-666.